Columnists

What’s New in Type II Diabetes?

Issue 22.17

Volunteers play a significant role in the development and progression of treatment for diabetes. Diabetes is a largely misunderstood disease. A greater knowledge of this disease can help us to prevent and control it. This knowledge is obtained through clinical research. Participants in clinical research are the “front-line” champions in the medical world. Every life-saving treatment started with a volunteer.
Type 2 diabetes is the most common form of diabetes. This form of diabetes starts with our body’s improper use of insulin and progresses until we are unable to produce enough insulin to keep our blood glucose at normal levels.
Although diabetes is a serious disease, it can be controlled. Education is an important and essential component to controlling diabetes. This includes gaining a better understanding of the current treatment options as well as the importance of lifestyle modifications. Diabetes has been a focus in research for many years and new medications continue to be developed and approved. The following are two examples of newer medications used in type II diabetes today.
GLP-1-RA is an acronym for a newer group of medications used in type II diabetes. Common brand names in this group of medications are Victoza® and Trulicity®. This medication is administered via injection. Some products within this group are only administered once weekly. The result of this medication is an increase in insulin production after eating and slower digestion of sugars. This medication will also commonly cause weight loss. The most common side effect of this medication is upset stomach, but this usually resolves after several days.
SGLT2 is another newer group of diabetes medications. Common brand names in this group of medications are Invokana® and Farxiga®. This medication is taken by mouth and increases the elimination of sugar in the urine. This medication can also cause weight loss and may be beneficial for patients with heart disease. This medication will usually cause increased urination and can cause urinary tract infections.
These newer diabetes treatments are an important focus in diabetes research. Our area is fortunate to have several physician groups conducting a variety of clinical trials to improve treatment in several therapeutic areas including diabetes. Chrysalis Clinical Research coordinates research for physicians and is currently enrolling trials for diabetes.
Our ongoing diabetes trials include both insulin and non-insulin therapies. These trials provide great education and a solid foundation for patients to build on. All trial related materials, tests, procedures, medications, and trial related visits with the doctor and research team are free for participants. Participants will gain a better understanding of diabetes and how to appropriately manage it with both medication and lifestyle modifications. Participants will be educated by physicians, nurses, pharmacists, and dieticians. Participants are also compensated for time and travel.
For more information or to see if you might qualify for a clinical trial contact Chrysalis Clinical Research at 435 656 1704 or visit our webpage www.sgccr.com.

Comments are closed.